Mark E. Strome, a director of HeartBeam, Inc. (NASDAQ: BEAT), bought 750,000 shares of common stock at $0.80 per share on April 16, 2026. The block purchase carried a value of $600,000. At the time of reporting, the shares were trading at $0.81, reflecting a 66% decline year-to-date and a 30% decrease over the past week.
The acquisition was made in connection with HeartBeams underwritten public offering of 12,500,000 shares of common stock. After the transaction, Strome directly or indirectly holds 3,650,000 shares.
The reported securities are held directly by three entities: Strome Mezzanine Fund II, LP; the Mark E. Strome Living Trust; and Strome Dynasty, LLC. Mr. Strome is reported to have the authority to vote and to dispose of the securities held by each of those entities.
Separately, HeartBeam completed a public offering of 12.5 million shares of common stock that generated $10 million in gross proceeds. The offering was priced at $0.80 per share. Lead participation came from ClearCardio, identified as the companys first commercial customer, as well as contributions from company executives, board members, and institutional investors. Underwriters were granted a 30-day option to purchase up to an additional 1.875 million shares to cover over-allotments. The offerings closing was conditioned on customary closing requirements.
Analyst interest has risen alongside the financing and regulatory progress. B. Riley and D. Boral Capital have each initiated coverage on HeartBeam with buy ratings, assigning price targets of $4.00 and $5.00, respectively. Analysts have focused in part on HeartBeams recent U.S. Food and Drug Administration clearance for a cable-free device that synthesizes a clinical-grade 12-lead ECG from 3D signal capture, a development cited in coverage notes.
InvestingPro analysis cited in reporting indicates the stock appears undervalued at current levels, and the companys next scheduled earnings report is set for May 7. The combination of insider buying, financing activity, and fresh analyst coverage frames the companys near-term outlook amid a sharp recent share-price decline.
Key points
- Director Mark E. Strome purchased 750,000 HeartBeam shares at $0.80 on April 16, 2026, for $600,000.
- The purchase relates to a 12.5 million-share underwritten offering that closed at $0.80 per share, raising $10 million in gross proceeds.
- Analysts B. Riley and D. Boral Capital initiated buy coverage, with price targets of $4.00 and $5.00; the company has FDA clearance for its cable-free 12-lead ECG device.
Risks and uncertainties
- HeartBeams share price has declined sharply year-to-date and over the last week, indicating market volatility in the companys equity - a potential concern for equity investors and the small-cap healthcare sector.
- The offerings completion was subject to customary closing conditions and underwriters were granted an over-allotment option, which could affect dilution and short-term supply of shares.
- Analyst coverage and price targets do not guarantee outcomes; market reaction to upcoming events such as the May 7 earnings report could introduce further uncertainty.
This article presents the reported transaction details and financing facts as disclosed. It does not speculate beyond the stated facts and reflects the information provided about holdings, offering size and pricing, analyst actions, and regulatory clearance.